WAVE Life Sciences Ltd.
WVE
$5.73
-$0.34-5.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -73.88% | 316.85% | -79.41% | 199.11% | -55.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -73.88% | 316.85% | -79.41% | 199.11% | -55.82% |
| Cost of Revenue | 18.00% | 16.78% | 18.30% | 11.35% | 7.62% |
| Gross Profit | -40.99% | 70.76% | -190.96% | 21.70% | -67.96% |
| SG&A Expenses | 37.76% | 20.41% | 29.51% | 20.24% | 25.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.78% | 17.91% | 21.27% | 13.73% | 12.38% |
| Operating Income | -39.89% | 37.16% | -345.86% | 11.83% | -50.75% |
| Income Before Tax | -37.42% | 44.35% | -281.79% | 12.83% | -53.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.42% | 44.35% | -281.79% | 12.83% | -53.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.42% | 44.35% | -281.79% | 12.83% | -53.29% |
| EBIT | -39.89% | 37.16% | -345.86% | 11.83% | -50.75% |
| EBITDA | -40.56% | 37.75% | -332.99% | 11.86% | -52.64% |
| EPS Basic | -10.46% | 54.82% | -263.00% | 31.12% | -21.09% |
| Normalized Basic EPS | -10.45% | 54.77% | -262.99% | 31.10% | -21.08% |
| EPS Diluted | -10.46% | 54.82% | -273.85% | 31.12% | -21.09% |
| Normalized Diluted EPS | -10.45% | 54.77% | -273.89% | 31.10% | -21.08% |
| Average Basic Shares Outstanding | 24.40% | 23.13% | 11.56% | 26.53% | 26.60% |
| Average Diluted Shares Outstanding | 24.40% | 23.13% | 4.56% | 26.53% | 26.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |